In 2020, Hofmann L et al. confirmed that CD16-positive exosomes could be used as an indicator of immunosuppressive grade of HNSC: the later the tumor stage or the more aggressive the tumor, the higher the CD16 level of total exosomes in patients (Hofmann et al., 2020). This evidence concerns the gene FCGR3A and neoplasm.